This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients

This study has been terminated.
(Company strategic decision)
Information provided by (Responsible Party):
Medgenics Medical Israel Ltd. Identifier:
First received: September 5, 2011
Last updated: September 12, 2016
Last verified: September 2016
September 5, 2011
September 12, 2016
October 2012
October 2013   (Final data collection date for primary outcome measure)
Viral Load: incidence of sustained virologic response (SVR) [ Time Frame: 24 weeks ]
Viral load to be measured along the study expecting notable decrease in the viral load by week 24 post intervention
Same as current
Complete list of historical versions of study NCT01433133 on Archive Site
  • Rapid virologic response (RVR) [ Time Frame: Time Frame-Study Week 4 ]
  • Early virologic response (EVR) [ Time Frame: Time Frame-Study week 12 ]
  • End-of-treatment response (EOT) [ Time Frame: Time Frame-Study week 48, 104 ]
  • Rapid virologic response (RVR) [ Time Frame: Evaluation after 4 weeks from treatment day 0 ]
Same as current
Not Provided
Not Provided
Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients
Phase I-II, Open Label, Uncontrolled, Dose Escalation Study of the Safety, Tolerability and Biologic Activity of the INFRADURE Biopump Secreting Sustained Interferon Alpha-2b (IFNα), in Combination With Oral Ribavirin for Genotype 3 Newly Diagnosed Hepatitis C Patients

This will be a Phase I-II, open-label, single center, uncontrolled, dose-escalation study. The trial will be conducted in Israel at the Tel Aviv Sourasky Medical Center.

All subjects will receive autologous InfraDure Biopump (micro-organ of dermis processed ex vivo transduced with genetic construct containing the gene for interferon)tissue implants intended to provide sustained production and delivery of therapeutic levels of INF for up to twenty four (24) weeks following INFRADURE Biopump implantation. Follow up will continue for a total of two years post INFRADURE Biopump implantation

Medgenics Inc. and Medgenics Medical Israel Ltd. are developing INFRADURE, an autologous dermal biopump capable of sustained secretion of therapeutic INF in the body, using a small tissue explant from the patient's own skin. The INFRADURE biopump is produced from a micro-organ (MO), typically measuring 30 mm in length and 1.5-2.5 mm diameter, which is harvested directly from the patient's dermis under local anesthesia. The micro-organ can be viably maintained ex-vivo for extended periods of time under standard culture conditions. INFRADURE Biopumps, produced by ex vivo transduction of MOs with Helper Dependent Adenoviral INF vectors (HDAd-INF), express and secrete INF. INFRADURE Biopump is monitored ex vivo prior to re-implantation, to attain true INF dosing. The INFRADURE Biopump is subsequently implanted subcutaneously back to the patient in order to provide continuous delivery of a known amount of INF. Each implanted autologous INFRADURE Biopump remains localized under the skin, and is accessible, so that if necessary, it can be removed or ablated at any time. The entire process from harvest to implantation requires 10-14 days
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hepatitis C
Biological: implantation
subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
Experimental: 1
• Genotype 3 chronic HCV with detectable serum HCV RNA
Intervention: Biological: implantation
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2014
October 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed patient consent form
  • Genotype 3 chronic HCV with detectable HCV RNA
  • No previous treatment for HCV infection
  • Hepatitis B and human immunodeficiency virus negative at screening visit
  • Able and willing to follow contraception requirements
  • Screening laboratory values, test, and physical exam within acceptable ranges

Exclusion Criteria:

  • Current enrollment in another investigational device or drug study
  • Anticipated inability to complete all clinic visits and comply with study procedures
  • History of, or any current medical condition, which could impact the safety of the subject during the study
  • Autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver disease, or other known liver disease other than HCV
  • Alcoholism or substance abuse with <6 documented months of sobriety
  • Known allergy or sensitivity to interferons or ribavirin
  • Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Plan to Share IPD: No
Medgenics Medical Israel Ltd.
Medgenics Medical Israel Ltd.
Not Provided
Not Provided
Medgenics Medical Israel Ltd.
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP